In fact, matching-adjusted indirect comparisons of dual immune checkpoint blockade with ipilimumab and nivolumab versus combined BRAF and MEK inhibition in patients with melanoma show that tentative benefits from immunotherapy emerge after the first 12 months of treatment25. Here, BRAF is linked to melanoma.